GLP-1 Cost Calculator: What You’ll Actually Pay in 2026

The 2026 GLP-1 All-In Cost Index

Quick answer: Across every legitimate GLP-1 path in 2026, first-month costs range from $0 (insured + savings offer) to $1,349+ (retail with no programs). The biggest savings come from stacking commercial insurance with a manufacturer savings card. The biggest surprises come from “starting at” prices that step up after month one or two. The table below separates each path’s intro price from its ongoing price and shows the realistic 12-month total.

We pulled prices from manufacturer pages, government sources, and provider sites — then assembled them into one table so you don’t have to open 20 tabs.

How much does GLP-1 cost per month in 2026?

Quick answer: GLP-1 medications cost $0–$1,349+ per month in 2026. Eligible commercially insured patients with a manufacturer savings offer can pay as little as $25/month for Wegovy or Zepbound. Cash-paying patients pay $149–$699/month through NovoCare, LillyDirect, or TrumpRx, depending on drug and dose. The retail list price ($1,028–$1,349+/month) is what you’d pay only without insurance, savings programs, or any direct-pay option.

Three things determine where you land:

1. 1.Your insurance situation. Commercial, Medicare, Medicaid, or no insurance — each has its own rules. A manufacturer savings card that drops your Wegovy cost to $25 with commercial insurance is illegal to use with Medicare.
2. 2.The drug. Wegovy and Zepbound (weight-loss-approved) follow different coverage rules than Ozempic and Mounjaro (diabetes-approved). Foundayo, the new oral GLP-1 approved April 2026, has its own pricing tier.
3. 3.The path. Same drug, different price. Wegovy through NovoCare maintenance is $349/month. Wegovy through TrumpRx for a starter dose is $199/month for two fills, then $349. Wegovy through insurance with a savings offer might be $25/month. Wegovy retail is $1,349/month. Same medication.

GLP-1 cost with insurance vs. without insurance

Quick answer: With commercial insurance that covers GLP-1s, eligible users may pay $0–$25/month using a manufacturer savings offer. With commercial insurance that doesn’t cover GLP-1s, the savings offer caps your cost around $499/month for Wegovy. With Medicare, you can’t use commercial savings cards — but the Medicare GLP-1 Bridge offers a $50/month copay starting July 1, 2026 for eligible Part D beneficiaries. Without any insurance, your cheapest legitimate paths are TrumpRx, NovoCare, or LillyDirect at $149–$699/month depending on drug and dose.

With commercial insurance that covers GLP-1s

If your employer or private plan covers Wegovy, Zepbound, Ozempic, or Mounjaro, you’ll pay a copay determined by your formulary tier. Preferred-tier copays often run $25–$75/month. Specialty-tier copays can run $100–$337/month. Stacking the manufacturer savings offer on top can bring the cost as low as $0–$25/month for Wegovy or Zepbound. The Wegovy Savings Offer caps savings at $100/month, so if your copay is over $125, you’ll still owe the difference.

Action: Verify coverage before paying cash. Skipping this step costs you potentially thousands of dollars.

With commercial insurance that doesn’t cover GLP-1s

If your plan excludes weight-loss medications (a plan exclusion), prior authorization will not fix it. Real options for plan-exclusion users:

• Wegovy Savings Offer for non-covered users (caps cost around $499/month)
• Zepbound Savings Card for non-covered users ($299–$499 depending on form and dose)
• NovoCare self-pay ($349–$499/month for Wegovy maintenance)
• LillyDirect ($299–$699/month for Zepbound depending on dose)
• TrumpRx ($149–$699/month depending on drug)
• Compounded telehealth (varies by provider)

With Medicare

Medicare cannot use commercial savings cards — that’s federal law. Through June 30, 2026, Medicare Part D covers GLP-1s for diabetes (Ozempic, Mounjaro) but typically not for weight loss.

Starting July 1, 2026, the Medicare GLP-1 Bridge offers a fixed $50 copay for eligible Part D beneficiaries. The Bridge runs through December 31, 2027.

With Medicaid

Medicaid coverage for GLP-1s varies dramatically by state. Four states eliminated coverage of GLP-1s for obesity treatment after October 2025: California, New Hampshire, Pennsylvania, and South Carolina. North Carolina briefly eliminated coverage but reinstated it in December 2025. KFF reported 13 state Medicaid programs covered obesity GLP-1s under fee-for-service as of January 2026. Always verify your state’s current Medicaid formulary before assuming coverage exists.

Without insurance

Your cheapest legitimate paths without insurance, ranked by typical first-month cost:

TrumpRx and the Medicare GLP-1 Bridge: what just changed in 2026

Quick answer: Two major pricing changes hit GLP-1s in 2026. TrumpRx launched February 5, 2026 at trumprx.gov with Wegovy pill at $149/month, Wegovy pen at $199/month for the first two fills (then $349), Ozempic at $199/month for the first two fills (then $349–$499), and Zepbound starting at $299/month. The Medicare GLP-1 Bridge launches July 1, 2026 and offers eligible Medicare Part D beneficiaries a fixed $50/month copay for Foundayo, Wegovy, or Zepbound KwikPen.

What is TrumpRx and how do I use it?

TrumpRx is a federal direct-to-consumer prescription drug platform launched February 5, 2026, using “Most-Favored-Nation” pricing — meaning U.S. patients pay closer to what patients in other developed countries pay.

People enrolled in government, state, or federally funded medical or prescription benefit programs are excluded from TrumpRx coupon terms. A valid prescription from a licensed clinician is required. TrumpRx routes you to LillyDirect or NovoCare for fulfillment with the discount applied.

Medicaid coverage shifts in 2026

State Medicaid programs are negotiating new pricing under federal Most-Favored-Nation agreements, but coverage for weight-loss-only GLP-1s pulled back in several states starting in late 2025:

• California (Medi-Cal): ended weight-loss GLP-1 coverage after October 2025
• New Hampshire: ended weight-loss GLP-1 coverage after October 2025
• Pennsylvania: ended weight-loss GLP-1 coverage after October 2025
• South Carolina: ended weight-loss GLP-1 coverage after October 2025
• North Carolina: briefly eliminated coverage in October 2025 due to a budget stalemate, then reinstated in December 2025

Always verify with your state’s Medicaid office before assuming coverage exists.

Why two people on the same insurance pay $25 and $499 for the same drug

Quick answer: GLP-1 cost varies wildly even on the same insurance because the final price is built from a stack — not a single number. Your real monthly cost equals: medication price + provider/membership fee + lab/consult fees + shipping − insurance coverage − savings offer discount. Each layer changes by plan, employer, formulary, deductible status, pharmacy, and savings card eligibility.

Why your coworker pays $25 and you pay $499

1. 1.Plan formulary tier. Same insurance company doesn't mean same formulary. Different employers negotiate different formularies.
2. 2.Deductible status. If your coworker met their deductible in March and you haven't, your share is much higher.
3. 3.Prior authorization. PA approved for them, denied for you, even with the same BMI.
4. 4.Pharmacy choice. Mail-order vs. retail vs. preferred network. Same drug, different price.
5. 5.Savings offer enrollment. Your coworker enrolled in the savings offer. You didn't.

The cheapest legitimate GLP-1 path by your situation

Quick answer: The cheapest path depends on your situation. Commercially insured with coverage: Wegovy or Zepbound + manufacturer savings offer = $0–$25/month. Medicare-eligible (after July 1, 2026) and meeting CMS criteria: Medicare GLP-1 Bridge at $50/month. No insurance, lowest cost: Wegovy oral 1.5mg via NovoCare, Foundayo 0.8mg via LillyDirect, or TrumpRx Wegovy pill at $149/month.

GLP-1 cost by medication

Quick answer: Wegovy (semaglutide for weight loss) costs $0–$1,349/month depending on path. Zepbound (tirzepatide for weight loss) runs $0–$1,087/month at list. Ozempic (semaglutide for diabetes) runs $0–$1,028/month. Mounjaro (tirzepatide for diabetes) costs $0–$1,112.16 per fill. Foundayo (orforglipron, the new oral GLP-1 approved April 2026) is one of the lowest-priced FDA-approved options at $149–$349/month via LillyDirect.

Wegovy cost (semaglutide, weight loss)

FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.

Zepbound cost (tirzepatide, weight loss)

FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

The Journey Program $449/month price applies to 7.5–15mg only when you refill within 45 days. Outside those terms, regular pricing of $499–$699 applies.

Ozempic cost (semaglutide, diabetes)

FDA-approved for type 2 diabetes. Prescribed off-label for weight loss but typically not covered by insurance for that purpose.

Mounjaro cost (tirzepatide, diabetes)

FDA-approved for type 2 diabetes. Prescribed off-label for weight loss but rarely covered by insurance for that purpose.

Foundayo cost (orforglipron, oral, weight loss)

FDA-approved April 1, 2026 for chronic weight management. An oral pill, not an injection.

Foundayo 0.8mg is tied with Wegovy oral 1.5mg at $149/month — both are among the lowest-priced FDA-approved branded GLP-1 entry-dose paths currently listed.

How manufacturer savings cards actually work

Quick answer: Manufacturer savings offers from Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) drop your monthly cost as low as $0–$25 if you have commercial insurance covering the drug. The Wegovy Savings Offer caps savings at $100/month. The Zepbound Savings Card has separate rules by form. Government beneficiaries (Medicare, Medicaid, TRICARE, VA) cannot legally use these offers. Terms change — verify current rules before each fill.

How the Wegovy Savings Offer works

How the Zepbound Savings Card works

• Single-dose pen, covered commercial: as little as $25/month, subject to maximum savings limits.
• Single-dose pen, no coverage: as low as $499/month under savings card terms.
• KwikPen, no coverage: as low as $299, $399, or $449 per month depending on dose.

Who cannot use savings cards

The federal anti-kickback statute prohibits manufacturer savings offers for prescriptions paid by:

• Medicare Part D
• Medicaid
• TRICARE
• Veterans Affairs
• Other federal/state health programs

Why your savings card might fail at the pharmacy

• The card expired and wasn’t renewed
• The pharmacy ran the card incorrectly (re-run or call manufacturer support)
• Your plan switched from covered to not-covered (formulary change)
• Your plan added a step-therapy requirement

If your savings card stops working, call Novo Nordisk (1-888-793-1218) or Eli Lilly support. Most cases are resolvable with a phone call.

Patient Assistance Programs: free GLP-1 if you qualify

Quick answer: The NovoCare Patient Assistance Program and the Lilly Cares Foundation provide free medication for qualifying patients, but eligibility is medicine-specific in 2026 — there is no universal rule across all GLP-1s. NovoCare PAP says private/commercial insurance users are not eligible, and Medicare Part D Ozempic patients are no longer eligible for Ozempic through PAP. Wegovy and Zepbound are generally not covered by either PAP. Verify current criteria with the manufacturer before applying.

NovoCare Patient Assistance Program

NovoCare’s PAP covers select Novo Nordisk diabetes medications. Per current NovoCare guidance:

• Private/commercial insurance users are not eligible
• Medicare Part D Ozempic patients are no longer eligible for Ozempic through PAP
• Eligibility criteria differ by medicine
• Wegovy is generally not on the PAP list

To check current eligibility: novocare.com/diabetes/help-with-costs/pap.html. Application takes 2–4 weeks for review.

Lilly Cares Foundation

Lilly Cares Foundation covers select Eli Lilly medications. Trulicity is listed under Group 1 with household income at or below 300% of the Federal Poverty Level. Mounjaro inclusion in the current program varies — verify against the active medication list before applying.

To check current eligibility: lillycares.com/how-to-apply.

Compounded GLP-1: real cost vs. real risk

Quick answer: Compounded GLP-1 medications are not FDA-approved finished products and should only be used when a patient’s medical needs cannot be met by an FDA-approved drug. With FDA shortages of semaglutide and tirzepatide resolved in 2024–2025, compounding pharmacies face restrictions on making products that are essentially copies of commercially available FDA-approved drugs. The FDA has warned consumers against products marketed as “research use only.”

What “compounded” actually means

A compounded medication is one made by a licensed pharmacy for a specific patient based on a clinician’s prescription. It’s not a generic. In 2024–2025, when the FDA officially recognized shortages of semaglutide and tirzepatide, compounding pharmacies were temporarily allowed to produce essentially-identical copies of Ozempic, Wegovy, Mounjaro, and Zepbound. Those shortages are now resolved.

Red flags to avoid

• No prescription required
• Marketed as “research peptides”
• Hides pharmacy information
• Claims to be a “generic” of Ozempic, Wegovy, Mounjaro, or Zepbound
• Suspiciously low pricing compared to legitimate compounded telehealth
• No clinician evaluation
• Sold from outside the U.S.

Verifying a legitimate compounded provider

The hidden costs nobody mentions

Quick answer: Advertised GLP-1 prices often exclude four real costs: introductory pricing that ends after 1–2 months (the “price cliff”), provider consultation fees ($49–$99 per visit at some platforms), lab work required before approval ($0–$200), and membership fees listed separately from medication prices. Always calculate your 12-month total, not your first-month price.

The price cliff

Many “starting at” prices are introductory offers that increase after the first 1–2 months.

Programs with similar cliffs:

Always run the 12-month math, not the first-month math.

Membership fees vs. medication fees

Here’s what major providers actually charge — membership vs. medication:

A “$99/month GLP-1 program” ad that doesn’t include medication means your real cost is $99 + $149–$349 medication = $250–$450/month.

The verification checklist

Before you commit to any GLP-1 program, verify:

9 ways to lower your GLP-1 cost

The highest-impact ways to lower your GLP-1 cost in 2026, ranked by typical impact:

1. 1.Verify insurance coverage before paying cash. If your plan covers Wegovy, the savings offer brings your cost as low as $0–$25/month. Skipping this step costs you potentially thousands.
2. 2.Stack a manufacturer savings offer. The Wegovy offer caps savings at $100/month. The Zepbound card has form-specific rules. Government beneficiaries excluded.
3. 3.Use TrumpRx, NovoCare, or LillyDirect. Direct manufacturer pricing bypasses pharmacy markups. Range $149–$699/month depending on drug, dose, and offer status.
4. 4.Apply for Patient Assistance Programs. Free medication if your household income is below the program's threshold. Eligibility is medicine-specific in 2026 — verify with the manufacturer before assuming.
5. 5.Consider compounded GLP-1. Legitimate clinician-supervised routes can be lower-cost. Not FDA-approved, not generic. Use the verification checklist above.
6. 6.Switch from injectable to oral. Wegovy oral 1.5mg ($149/month through August 2026) and Foundayo 0.8mg ($149/month) are among the lowest-priced FDA-approved branded options.
7. 7.Use HSA/FSA dollars when applicable. GLP-1 medication may be HSA/FSA eligible when prescribed to treat a diagnosed medical condition. IRS guidance ties weight-loss treatment eligibility to a specific disease diagnosed by a physician. Plan administrators can require documentation.
8. 8.Wait at a dose plateau. If your weight-loss goals are met at 1mg or 1.7mg Wegovy, you may not need to titrate to 2.4mg. Lower doses are cheaper through some self-pay programs. Discuss with your clinician.
9. 9.Appeal a PA denial. Many PA denials are reversible with proper documentation: BMI, comorbidities, prior weight-loss attempts, step-therapy attempts. Outcomes vary by insurer and state.

What to do if your insurance denies GLP-1 coverage

Quick answer: Insurance denials fall into two categories: prior authorization (PA) denials and plan exclusions. PA denials are often reversible with proper documentation and appeals. Plan exclusions mean weight-loss medications aren’t part of your benefit at all — PA cannot fix this. Your denial letter will tell you which one you got.

Read your denial letter carefully

If you got a PA denial (not exclusion)

PA denials are appealable. A recent New York State analysis found prescription-drug and dental denials were overturned more than 50% of the time; several major insurers had overturn percentages around 40–50%. The process:

1. Get the specific denial reason in writing.
2. Work with your prescriber on a stronger appeal letter including: current BMI documentation, weight-related comorbidities, prior weight-loss attempts, prior step-therapy attempts, and clinical rationale for this specific medication.
3. Submit through your plan’s appeals process.
4. If denied again, escalate to external review. Independent reviewers overturn additional denials.

If you got a plan exclusion

Skip the appeal. Your real options:

• TrumpRx: $149–$699/month depending on drug and dose
• NovoCare or LillyDirect: $149–$699/month direct from manufacturer
• Wegovy or Zepbound Savings Offer (no-coverage scenario): caps at $499/month for Wegovy; $299–$499 for Zepbound
• Compounded telehealth: varies by provider
• Manufacturer Patient Assistance Program: free if you qualify (medicine-specific eligibility)

How accurate is this GLP-1 cost calculator, and how do we verify prices?

Quick answer: The GLP-1 cost calculator is accurate as a cost-path estimate, not as a guaranteed pharmacy quote. It uses verified public prices, savings-offer terms, provider fee structures, and government program rules. Your exact price still depends on your specific insurance plan, formulary, deductible status, dose, pharmacy, eligibility, and current offer terms.

Sources we use

Primary (authoritative):

• Manufacturer pricing pages: NovoCare.com, Wegovy.com, LillyDirect, Zepbound.lilly.com, Foundayo.lilly.com, pricinginfo.lilly.com
• Government sources: CMS Medicare GLP-1 Bridge program documentation, trumprx.gov, FDA compounding guidance and unapproved-GLP-1 warnings
• Clinical references: FDA-approved labeling, prescribing information

Secondary (cross-checks):

• KFF (Kaiser Family Foundation) Medicaid coverage tracking
• Provider pricing pages for membership and bundled-pricing details

Voice-of-customer only (never used as evidence for facts):

• Reddit, forums, comment sections — used only to capture how real searchers describe the problem in their own words

Update cadence

How affiliate priority works

We rank paths by total all-in monthly cost. When two paths have the same estimated all-in monthly cost and equal fit, we use partner priority as a tiebreaker and disclose it openly.

• For FDA-approved branded drug paths: Ro primary, Sesame secondary
• For compounded medication paths: Eden → MEDVi → Ro → SHED → Sesame and beyond
• For manufacturer-direct paths (NovoCare, LillyDirect, TrumpRx): we earn no commission, but surface them prominently because they’re often the right answer

We do not accept payment for higher rankings. We do not promote a paid path over a cheaper unpaid path.

When to talk to a clinician before using a GLP-1 cost estimate

Frequently asked questions

Why this page exists

We built this because every GLP-1 cost page we read either pushed users into one provider’s funnel, asked irrelevant budget questions, or gave a “$25 to $1,400” range that doesn’t help anyone. Real people ask “Am I cooked?” when they see a $1,295 pharmacy bill. They deserve better than another article that buries the answer.

The calculator above gives you a routed answer in 60 seconds. The All-In Cost Index gives you the verified price for every legitimate path in one place. The breakdowns by drug, situation, and insurance type answer the follow-up questions you’d otherwise have to search again.

If your situation is unusual, take the Find My GLP-1 Path quiz — it’s an 8-step deeper match across our affiliate provider network. This page is updated continuously as manufacturer prices, government programs, and provider terms change. Last verified May 7, 2026.

Your privacy

Important disclosures

About this page